

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



130

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : A61K 31/435, C07D 471/04 | A1 | (11) International Publication Number: WO 99/27928 (43) International Publication Date: 10 June 1999 (10.06.99) |
| (21) International Application Number: PCT/US98/25325 (22) International Filing Date: 30 November 1998 (30.11.98) (30) Priority Data: 60/067,552 4 December 1997 (04.12.97) US 9807364.6 6 April 1998 (06.04.98) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CICCARONE, Terrence, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). deSOLMS, S., Jane [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; PECORARO, Dianne, 126 East Lincoln Avenue, Rahway, NJ 07065 (US). | | (81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE (57) Abstract The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. | | |

JC555 U.S. PTO
09/997323



11/30/01

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

TITLE OF THE INVENTION

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

BACKGROUND OF THE INVENTION

5 The Ras protein is part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein. In the inactive state, Ras is bound to GDP. Upon growth factor receptor
10 activation Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M. Willumsen, *Ann.*
15 *Rev. Biochem.* 62:851-891 (1993)). Mutated *ras* genes are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.

20 Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus contains a sequence motif termed a "CAAX" or "Cys-Aaa¹-Aaa²-
25 Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen *et al.*, *Nature* 310:583-586 (1984)). Depending on the specific sequence, this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of
30 the cysteine residue of the CAAX motif with a C₁₅ or C₂₀ isoprenoid, respectively. (S. Clarke., *Ann. Rev. Biochem.* 61:355-386 (1992); W.R. Schafer and J. Rine, *Ann. Rev. Genetics* 30:209-237 (1992)). The Ras protein is one of several proteins that are known to undergo post-translational farnesylation. Other farnesylated proteins include the

Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., *J. Biol. Chem.* 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, 5 et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above.

Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar and to modify other aspects of their transformed phenotype. It has also been 10 demonstrated that certain inhibitors of farnesyl-protein transferase selectively block the processing of the Ras oncoprotein intracellularly (N.E. Kohl *et al.*, *Science*, 260:1934-1937 (1993) and G.L. James *et al.*, *Science*, 260:1937-1942 (1993). Recently, it has been shown that an inhibitor of farnesyl-protein transferase blocks the growth of *ras*- 15 dependent tumors in nude mice (N.E. Kohl *et al.*, *Proc. Natl. Acad. Sci U.S.A.*, 91:9141-9145 (1994) and induces regression of mammary and salivary carcinomas in *ras* transgenic mice (N.E. Kohl *et al.*, *Nature Medicine*, 1:792-797 (1995).

Indirect inhibition of farnesyl-protein transferase *in vivo* 20 has been demonstrated with lovastatin (Merck & Co., Rahway, NJ) and compactin (Hancock *et al.*, *ibid*; Casey *et al.*, *ibid*; Schafer *et al.*, *Science* 245:379 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids including farnesyl pyrophosphate. Farnesyl-protein transferase utilizes 25 farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss *et al.*, *Cell*, 62:81-88 (1990); Schaber *et al.*, *J. Biol. Chem.*, 265:14701-14704 (1990); Schafer *et al.*, *Science*, 249:1133-1139 (1990); Manne *et al.*, *Proc. Natl. Acad. Sci USA*, 87:7541-7545 (1990)). Inhibition of farnesyl pyrophosphate 30 biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. However, direct inhibition of farnesyl-protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.

Inhibitors of farnesyl-protein transferase (FPTase) have been described in two general classes. The first are analogs of farnesyl diphosphate (FPP), while the second class of inhibitors is related to the protein substrates (e.g., Ras) for the enzyme. The peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. (Schaber *et al.*, *ibid*; Reiss *et al.*, *ibid*; Reiss *et al.*, *PNAS*, 88:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141,851, University of Texas; N.E. Kohl *et al.*, *Science*, 260:1934-1937 (1993); Graham, *et al.*, *J. Med. Chem.*, 37, 725 (1994)). In general, deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound. However, the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.


It has recently been shown that farnesyl-protein transferase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and therapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7-112930). It has also recently been disclosed that certain 1,2,3,4-tetrahydroisoquinoline peptidomimetic compounds, some of which incorporate an imidazole moiety, are inhibitors of FPTase (U.S. Pat. No. 5,439,918, EP 0 618 221 A2 and EP 0 675 112 A1).

It is, therefore, an object of this invention to develop novel peptidomimetic compounds that do not have a thiol moiety, and that will inhibit farnesyl-protein transferase and thus, the post-translational farnesylation of proteins. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention.

SUMMARY OF THE INVENTION

The present invention comprises non-thiol compounds which inhibit farnesyl-protein transferase. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.


The compounds of this invention are illustrated by the formula A:



10

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention are useful in the inhibition of farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. In a first embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula A:





wherein:

R^{1a}, R^{1b} and R^{1c} are independently selected from:











- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-,
- c) C₁-C₆ alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)-NR⁸-;

R² is selected from: H; unsubstituted or substituted C₁-8 alkyl, unsubstituted or substituted C₂-8 alkenyl, unsubstituted or substituted aryl,

unsubstituted or substituted heterocycle, ,  and -S(O)₂R⁶,

wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:
 - a) C₁-4 alkyl,
 - b) (CH₂)_pOR⁶,
 - c) (CH₂)_pNR⁶R⁷,
 - d) halogen,
 - e) C₁-4 perfluoroalkyl,
- 2) C₃-6 cycloalkyl,
- 3) OR⁶,
- 4) SR⁶, S(O)R⁶, SO₂R⁶,



5

15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} and R^{3b} are independently absent or selected from: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or

substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:


- 5 a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, R⁸₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
10 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NH-, CN, H₂N-C(NH)-, R⁸C(O)-, R⁸OC(O)-, N₃,
15 -N(R⁸)₂, or R⁸OC(O)NH-;

R⁵ is independently selected from:

- a) hydrogen,
 b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl,
20 perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C-(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
 c) C₁-C₆ alkyl, unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-;
25

R⁶, R⁷ and R^{7a} are independently selected from: H; C₁-4 alkyl, C₃-6 cycloalkyl, heterocycle, aryl, C₁-4 perfluoroalkyl, unsubstituted or substituted with one or two substituents selected from:

- 30 a) C₁-4 alkoxy,
 b) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle,
 c) halogen,
 d) HO,



h) $\text{N}(\text{R}^8)_2$; or

- 5 R^6 and R^7 may be joined in a ring;
 R^7 and R^{7a} may be joined in a ring;




R^8 is independently selected from hydrogen, C_1 - C_6 alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

10

R^9 is independently selected from C_1 - C_6 alkyl and aryl;

- R^{10} is selected from: H; $\text{R}^8\text{C}(\text{O})-$; $\text{R}^9\text{S}(\text{O})_m-$; unsubstituted or substituted C_1 -4 alkyl, unsubstituted or substituted C_3 -6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted aryl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:

- 15 a) C_1 -4 alkoxy,
 20 b) aryl or heterocycle,
 c) halogen,
 d) HO,



h) $\text{N}(\text{R}^8)_2$, or

i) C₃₋₆ cycloalkyl;

5

R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A^1 and A^2 are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^8-$, $-\text{NR}^8\text{C}(\text{O})-$, O, $-\text{N}(\text{R}^8)-$, $-\text{S}(\text{O})_2\text{N}(\text{R}^8)-$, $-\text{N}(\text{R}^8)\text{S}(\text{O})_2-$, or $\text{S}(\text{O})_m$;

15

J and K are independently selected from N, NH or CH_y ;

V is selected from:

- a) hydrogen,
- 20 b) heterocycle,
- c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl,

25 provided that V is not hydrogen if A^1 is $\text{S}(\text{O})_m$ and V is not hydrogen if A^1 is a bond, n is 0 and A^2 is $\text{S}(\text{O})_m$;

W is a heterocycle;

X is a bond, $-C(=O)NR^{10}$ -, $-NR^{10}C(=O)-$, $-S(O)_m$ -, $-NR^{10}$ -, O or $-C(=O)-$;

m is 0, 1 or 2;

5 n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

r is 0 to 5, provided that r is 0 when V is hydrogen;

s is 1 or 2;

10 t is 0 or 1; and


y is 1 or 2;

the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

15

In a further embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula B:



B

wherein:

20

R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₁-C₆ alkyl;

R^{1b} is independently selected from:

25 a) hydrogen,

- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₆ cycloalkyl, R⁸O-, -N(R⁸)₂ or C₂-C₆ alkenyl,
- c) C₁-C₆ alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;


R² is selected from:

- a) C₁-8 alkyl, unsubstituted or substituted with one or more of:


1) aryl or heterocycle, unsubstituted or substituted with:

- i) C₁-4 alkyl,
 ii) (CH₂)_pOR⁶,
 iii) (CH₂)_pNR⁶R⁷,
 iv) halogen,
 v) C₁-4 perfluoroalkyl,

- 2) OR⁶,
 3) SR⁶, SO₂R⁶, or
 4)




b)



- c) aryl, unsubstituted or substituted with one or more of:

- 1) C₁-8 alkyl,
 2) C₁-8 perfluoroalkyl,
 3) OR⁶,
 4) SR⁶, SO₂R⁶, or
 5)



d) $-\text{SO}_2\text{R}^6$;

R^{3a} and R^{3b} are independently absent or selected from:

5 H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R^4 is independently selected from:

10 a) hydrogen,
 b) $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ perfluoroalkyl, F, Cl, $\text{R}^8\text{O}-$, $\text{R}^8\text{C}(\text{O})\text{NR}^8-$, CN, NO_2 , $(\text{R}^8)_2\text{N-C}(\text{NR}^8)-$, $\text{R}^8\text{C}(\text{O})-$, $\text{R}^8\text{OC}(\text{O})-$, $-\text{N}(\text{R}^8)_2$, or $\text{R}^9\text{OC}(\text{O})\text{NR}^8-$, and
 15 c) $\text{C}_1\text{-C}_6$ alkyl substituted by $\text{C}_1\text{-C}_6$ perfluoroalkyl, $\text{R}^8\text{O}-$, $\text{R}^8\text{C}(\text{O})\text{NR}^8-$, $(\text{R}^8)_2\text{N-C}(\text{NR}^8)-$, $\text{R}^8\text{C}(\text{O})-$, $\text{R}^8\text{OC}(\text{O})-$, $-\text{N}(\text{R}^8)_2$, or $\text{R}^9\text{OC}(\text{O})\text{NR}^8-$;

R^5 is selected from:

20 a) hydrogen,
 b) $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_1\text{-C}_6$ perfluoroalkyl, F, Cl, $\text{R}^8\text{O}-$, $\text{R}^9\text{S}(\text{O})_{\text{m}}-$, $\text{R}^8\text{C}(\text{O})\text{NR}^8-$, CN, NO_2 , $(\text{R}^8)_2\text{N-C}(\text{NR}^8)-$, $\text{R}^8\text{C}(\text{O})-$, $\text{R}^8\text{OC}(\text{O})-$, $-\text{N}(\text{R}^8)_2$, or $\text{R}^9\text{OC}(\text{O})\text{NR}^8-$, and
 25 c) $\text{C}_1\text{-C}_6$ alkyl unsubstituted or substituted by $\text{C}_1\text{-C}_6$ perfluoroalkyl, F, Cl, $\text{R}^8\text{O}-$, $\text{R}^9\text{S}(\text{O})_{\text{m}}-$, $\text{R}^8\text{C}(\text{O})\text{NR}^8-$, CN, $(\text{R}^8)_2\text{N-C}(\text{NR}^8)-$, $\text{R}^8\text{C}(\text{O})-$, $\text{R}^8\text{OC}(\text{O})-$, $-\text{N}(\text{R}^8)_2$, or $\text{R}^9\text{OC}(\text{O})\text{NR}^8-$;

R^6 , R^7 and R^{7a} are independently selected from:

30 H; $\text{C}_1\text{-4}$ alkyl, $\text{C}_3\text{-6}$ cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:
 a) $\text{C}_1\text{-4}$ alkoxy,
 b) halogen, or




c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

5 R^8 is independently selected from hydrogen, C_1 - C_6 alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R^9 is independently selected from C_1 - C_6 alkyl and aryl;

10 R^{10} is selected from: H; $R^8C(O)-$; $R^9S(O)_m-$; unsubstituted or substituted C_{1-4} alkyl, unsubstituted or substituted C_{3-6} cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:

- 15 a) C_{1-4} alkoxy,
b) aryl or heterocycle,
c) halogen,
d) HO,



20

- h) $N(R^8)_2$, or
i) C_{3-6} cycloalkyl;

25 R^{11} is selected from
H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl,

unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

5 A^1 and A^2 are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$,
 $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^8-$, O , $-\text{N}(\text{R}^8)-$, or $\text{S}(\text{O})_m$;

J and K are independently selected from N or CH_y ;

V is selected from:

- 10 a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl, and
 b) aryl;

15 W is a heterocycle selected from pyrrolidinyl, triazolyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, or isoquinolinyl;

X is a bond, $-\text{C}(=\text{O})\text{NR}^{10}-$, $-\text{NR}^{10}\text{C}(=\text{O})-$, $-\text{S}(\text{O})_m-$ or $-\text{NR}^{10}-$;


- 20 m is 0, 1 or 2;
 n is 0, 1, 2, 3 or 4;
 p is 1, 2 or 3;
 q is 0 or 1;
 r is 0 to 5, provided that r is 0 when V is hydrogen;
25 s is 1 or 2;
 t is 1; and
 y is 1 or 2;

the dashed lines represent optional double bonds;

30

or an optical isomer or pharmaceutically acceptable salt thereof.

In another embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula C:



C

wherein:



- 5 R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₁-C₆ alkyl;

R^{1b} is independently selected from:


- 10 a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₆ cycloalkyl, R⁸O-, -N(R⁸)₂ or C₂-C₆ alkenyl,
 c) C₁-C₆ alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;
- 15

R² is selected from:

- a) C₁-8 alkyl, unsubstituted or substituted with one or more of:
- 20 1) aryl or heterocycle, unsubstituted or substituted with:
- i) C₁-4 alkyl,
 ii) (CH₂)_pOR⁶,
 iii) (CH₂)_pNR⁶R⁷,
 iv) halogen,
 v) C₁-4 perfluoroalkyl,
- 25 2) OR⁶,
 3) SR⁶, SO₂R⁶, or



5 c) aryl, unsubstituted or substituted with one or more of:

- 1) C₁₋₈ alkyl,
 2) C₁₋₈ perfluoroalkyl,
 3) OR⁶,
 10 4) SR⁶, SO₂R⁶, or
 5)  ;

d) -SO₂R⁶;

R^{3a} and R^{3b} are independently absent or selected from:

15 H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;




20 R⁴ is independently selected from:

- a) hydrogen,
 b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
 25 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

R⁵ is selected from:

- 30 a) hydrogen,

- b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- 5 c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;
- 10 R⁶, R⁷ and R^{7a} are independently selected from:
H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle,
unsubstituted or substituted with:
a) C₁-4 alkoxy,
b) halogen, or
15 c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;
- R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;
- 20 R⁹ is independently selected from C₁-C₆ alkyl and aryl;
- R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, unsubstituted or substituted C₃-6 cycloalkyl, unsubstituted or
25 substituted heterocycle, unsubstituted or substituted aryl, substituted aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:
a) C₁-4 alkoxy,
30 b) aryl or heterocycle,
c) halogen,
d) HO,



h) $\text{N(R}^8)_2$, or

i) C₃₋₆ cycloalkyl;

5

R¹¹ is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A¹ and A² are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C(O)}-$, $-\text{C(O)NR}^8-$, O, $-\text{N(R}^8)-$, or S(O)_m ;

15 V is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl; and
- b) aryl;

20

W is a heterocycle selected from pyrrolidinyl, triazolyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, or isoquinolinyl;

X is a bond, $-\text{C(=O)NR}^{10}-$, $-\text{NR}^{10}\text{C(=O)}-$, $-\text{S(O)}_m-$ or $-\text{NR}^{10}-$;

25

m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 1, 2 or 3;


- q is 0 or 1;
 r is 0 to 5, provided that r is 0 when V is hydrogen;
 s is 1 or 2; and
 t is 1;

5

the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

- 10 In a preferred embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula D:



wherein:

- 15 R1a and R1c are independently selected from: hydrogen, C3-C10 cycloalkyl, R8O-, -N(R8)2, F or C1-C6 alkyl;

R1b is independently selected from:

- 20 a) hydrogen,
 b) aryl, heterocycle, C3-C10 cycloalkyl, R8O-, -N(R8)2, F or C2-C6 alkenyl,
 c) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from
 25 unsubstituted or substituted aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R8O- and -N(R8)2;

R2 is selected from: H; unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted aryl,

unsubstituted or substituted heterocycle, $\text{S(O)}_2\text{R}^6$, C(=O)R^6 , $\text{C(=O)NR}^6\text{R}^7$ and -

wherein the substituted group is substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:








- a) C₁₋₄ alkyl,
- b) $(\text{CH}_2)_p\text{OR}^6$,
- c) $(\text{CH}_2)_p\text{NR}^6\text{R}^7$,
- d) halogen,
- e) C₁₋₄ perfluoroalkyl,

- 2) C₃₋₆ cycloalkyl,
- 3) OR^6 ,
- 4) SR^6 , S(O)R^6 , SO_2R^6 ,

5) $-\text{NR}^6\text{R}^7$,

6) $\begin{array}{c} \text{R}^6 \\ | \\ -\text{N}-\text{C(=O)}-\text{R}^7 \end{array}$,

7) $\begin{array}{c} \text{R}^6 \\ | \\ -\text{N}-\text{C(=O)}-\text{NR}^7\text{R}^{7a} \end{array}$,



15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} and R^{3b} are independently absent or selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

a) hydrogen,

b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆

- perfluoroalkyl, F, Cl, R^8O- , $R^8C(O)NR^8-$, CN, NO_2 , $(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$, and
- c) C_1-C_6 alkyl substituted by C_1-C_6 perfluoroalkyl, R^8O- , $R^8C(O)NR^8-$, $(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$;




R^{5a} and R^{5b} are independently hydrogen, C_1-C_6 alkyl, cyclopropyl, trifluoromethyl and halogen;

- 10 R^6 , R^7 and R^{7a} are independently selected from:
H; C_1-4 alkyl, C_3-6 cycloalkyl, aryl, heterocycle,
unsubstituted or substituted with:
a) C_1-4 alkoxy,
b) halogen, or
15 c) substituted or unsubstituted aryl or substituted or
unsubstituted heterocycle;

R^8 is independently selected from hydrogen, C_1-C_6 alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;

- 20 R^9 is independently selected from C_1-C_6 alkyl and aryl;

- R^{10} is selected from: H; $R^8C(O)-$; $R^9S(O)_m-$; unsubstituted or substituted C_1-4 alkyl, unsubstituted or substituted C_3-6 cycloalkyl, unsubstituted or
25 substituted heterocycle, unsubstituted or substituted aryl, substituted
aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl,
unsubstituted or substituted heteroarylsulfonyl, wherein the substituted
group is substituted with one or two substituents selected from:
a) C_1-4 alkoxy,
30 b) aryl or heterocycle,
c) halogen,
d) HO,



h) $\text{N}(\text{R}^8)_2$, or

i) C₃₋₆ cycloalkyl;

5

R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A^1 and A^2 are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^8-$, O, $-\text{N}(\text{R}^8)-$, or $\text{S}(\text{O})_m$;

15 J and K are independently selected from N or CH_y ;

V is selected from:

- a) hydrogen,
- b) heterocycle selected from pyrrolidinyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
- c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl, and

25

provided that V is not hydrogen if A^1 is $\text{S}(\text{O})_m$ and V is not hydrogen if A^1 is a bond, n is 0 and A^2 is $\text{S}(\text{O})_m$;

X is a bond, $-C(=O)NR^{10}$ -, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;

m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

5 p is 0, 1, 2, 3 or 4;

q is 0 or 1;


r is 0 to 5, provided that r is 0 when V is hydrogen; and

y is 1 or 2;

10 the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

In a preferred embodiment of this invention, the inhibitors
15 of farnesyl-protein transferase are illustrated by the formula E:



E

wherein:

20 R1a and R1c are independently selected from: hydrogen, C3-C10 cycloalkyl, R^8O- , $-N(R^8)_2$, F or C1-C6 alkyl;

R1b is independently selected from:

- a) hydrogen,
- 25 b) aryl, heterocycle, C3-C10 cycloalkyl, R^8O- , $-N(R^8)_2$, F or C2-C6 alkenyl,
- c) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from

unsubstituted or substituted aryl, heterocycle, C₃-C₁₀
cycloalkyl, C₂-C₆ alkenyl, R⁸O- and -N(R⁸)₂;

- R² is selected from: H; unsubstituted or substituted C₁-8 alkyl,
5 unsubstituted or substituted C₂-8 alkenyl, unsubstituted or substituted aryl,

unsubstituted or substituted heterocycle, $\text{C}(=\text{O})\text{R}^6$, $\text{C}(=\text{O})\text{NR}^6\text{R}^7$ and -
S(O)₂R⁶,

wherein the substituted group is substituted with one or more of:








- 1) aryl or heterocycle, unsubstituted or substituted with
10 one or two groups selected from:
a) C₁-4 alkyl,
b) (CH₂)_pOR⁶,
c) (CH₂)_pNR⁶R⁷,
d) halogen,
15 e) C₁-4 perfluoroalkyl,
2) C₃-6 cycloalkyl,
3) OR⁶,
4) SR⁶, S(O)R⁶, SO₂R⁶,

5) $\text{—NR}^6\text{R}^7$,

6) $\begin{array}{c} \text{R}^6 \\ | \\ \text{—N—C(=O)—R}^7 \end{array}$,

7) $\begin{array}{c} \text{R}^6 \\ | \\ \text{—N—C(=O)—NR}^7\text{R}^{7a} \end{array}$,

20



15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} and R^{3b} are independently absent or selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆

- perfluoroalkyl, F, Cl, R^8O- , $R^8C(O)NR^8-$, CN, NO_2 , $(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$, and
- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R^8O- , $R^8C(O)NR^8-$, $(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$;




R^{5a} and R^{5b} are independently hydrogen, C₁-C₆ alkyl, cyclopropyl, trifluoromethyl and halogen;

- 10 R^6 , R^7 and R^{7a} are independently selected from:
H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle,
unsubstituted or substituted with:
a) C₁-4 alkoxy,
b) halogen, or
15 c) substituted or unsubstituted aryl or substituted or
unsubstituted heterocycle;

R^8 is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;

20 R^9 is independently selected from C₁-C₆ alkyl and aryl;

- R^{10} is selected from: H; $R^8C(O)-$; $R^9S(O)_m-$; unsubstituted or substituted C₁-4 alkyl, unsubstituted or substituted C₃-6 cycloalkyl, unsubstituted or
25 substituted heterocycle, unsubstituted or substituted aryl, substituted
aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl,
unsubstituted or substituted heteroarylsulfonyl, wherein the substituted
group is substituted with one or two substituents selected from:
a) C₁-4 alkoxy,
30 b) aryl or heterocycle,
c) halogen,
d) HO,



h) $\text{N(R}^8)_2$, or

i) C₃₋₆ cycloalkyl;

5

R¹¹ is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A¹ and A² are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C(O)}-$, $-\text{C(O)NR}^8-$, O, $-\text{N(R}^8)-$, or S(O)_m ;

15 V is selected from:

a) hydrogen,

b) heterocycle selected from pyrrolidinyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinoliny, isoquinoliny, triazolyl and thienyl,

20

c) aryl,

d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and

e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if

25 A¹ is a bond, n is 0 and A² is S(O)_m ;

X is a bond, $-\text{C(=O)NR}^{10}-$, $-\text{NR}^{10}\text{C(=O)}-$, $-\text{S(O)}_m-$ or $-\text{NR}^{10}-$;


- m is 0, 1 or 2;
 n is 0, 1, 2, 3 or 4;
 p is 0, 1, 2, 3 or 4;
 q is 0 or 1; and
 5 r is 0 to 5, provided that r is 0 when V is hydrogen;

the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

10

In a preferred embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula F:



15 wherein:

R1a and R1c are independently selected from: hydrogen, C3-C10 cycloalkyl or C1-C6 alkyl;

20 R1b is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C3-C10 cycloalkyl, R⁸O-, -N(R⁸)₂, F or C2-C6 alkenyl,
- c) C1-C6 alkyl unsubstituted or substituted by aryl,
- 25 heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R⁸O-, or -N(R⁸)₂;

R^2 is selected from: H; unsubstituted or substituted C_{1-8} alkyl,

unsubstituted or substituted aryl, $\begin{array}{c} \text{R}^6 \\ \diagup \\ \text{C} \\ \parallel \\ \text{O} \end{array}$, $\begin{array}{c} \text{NR}^6\text{R}^7 \\ \diagup \\ \text{C} \\ \parallel \\ \text{O} \end{array}$ and $-\text{S}(\text{O})_2\text{R}^6$,

wherein the substituted group is substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:








- a) C_{1-4} alkyl,
- b) $(\text{CH}_2)_p\text{OR}^6$,
- c) $(\text{CH}_2)_p\text{NR}^6\text{R}^7$,
- d) halogen,
- e) C_{1-4} perfluoroalkyl,

- 2) C_{3-6} cycloalkyl,
- 3) OR^6 ,
- 4) SR^6 , $\text{S}(\text{O})\text{R}^6$, SO_2R^6 ,

5) $-\text{NR}^6\text{R}^7$,

6) $\begin{array}{c} \text{R}^6 \\ | \\ -\text{N} \\ \diagup \\ \text{C} \\ \parallel \\ \text{O} \end{array} \text{R}^7$,

7) $\begin{array}{c} \text{R}^6 \\ | \\ -\text{N} \\ \diagup \\ \text{C} \\ \parallel \\ \text{O} \end{array} \text{NR}^7\text{R}^{7a}$,



15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and

- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

5 R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:




- 10 a) C₁-4 alkoxy,
b) halogen, or
c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

15 R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

20 R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

- 25 a) C₁-4 alkoxy,
b) aryl or heterocycle,
c) halogen,
d) HO,



- h) $N(R^8)_2$, or
 i) C3-6 cycloalkyl;

5 R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10


A^1 is selected from: a bond, $-C(O)-$, O, $-N(R^8)-$, or $S(O)_m$;

X is a bond, $-C(=O)NR^{10}-$, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;

- 15 n is 0 or 1; provided that n is not 0 if A^1 is a bond, O, $-N(R^8)-$, or $S(O)_m$;
 m is 0, 1 or 2;
 p is 0, 1, 2, 3 or 4;
 r is 1 or 2; and
 20 q is 0 or 1;

or an optical isomer or pharmaceutically acceptable salt thereof.

25 In a preferred embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula G:



wherein:



R^{1a} and R^{1c} are independently selected from: hydrogen, R⁸O-, -N(R⁸)₂, F, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

5

R^{1b} is independently selected from:











- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₂-C₆ alkenyl,
- 10 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;

R² is selected from: H; unsubstituted or substituted C₁-8 alkyl,

15 unsubstituted or substituted aryl, ,  and -S(O)₂R⁶,

wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:
 - a) C₁-4 alkyl,
 - 20 b) (CH₂)_pOR⁶,
 - c) (CH₂)_pNR⁶R⁷,
 - d) halogen,
 - e) C₁-4 perfluoroalkyl,
- 2) C₃-6 cycloalkyl,
- 25 3) OR⁶,
- 4) SR⁶, S(O)R⁶, SO₂R⁶,



5

15) C₁₋₈ alkyl, or16) C₁₋₈ perfluoroalkyl;

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

5

R⁴ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

15

R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

- H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:
- a) C₁-4 alkoxy,
 - b) halogen, or
 - c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

25

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;




R⁹ is independently selected from C₁-C₆ alkyl and aryl;

30

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

- a) C₁-4 alkoxy,

- b) aryl or heterocycle,
- c) halogen,
- d) HO,



5

- h) $\text{N}(\text{R}^8)_2$, or
- i) C_{3-6} cycloalkyl;

R^{11} is selected from

- 10 H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

- 15 X is a bond, $-\text{C}(=\text{O})\text{NR}^{10}-$, $-\text{NR}^{10}\text{C}(=\text{O})-$, $-\text{S}(\text{O})_m-$ or $-\text{NR}^{10}-$;

n is 0 or 1;

m is 0, 1 or 2;

p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond, $-\text{NR}^8-$ or


20 O;

q is 0 or 1; and

r is 1 or 2;

or an optical isomer or pharmaceutically acceptable salt thereof.

- 25 In a preferred embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula H:





wherein:

R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀
 5 cycloalkyl or C₁-C₆ alkyl;

R^{1b} is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂ or F,
- 10 c) C₁-C₆ alkyl unsubstituted or substituted by aryl,
 heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, or -N(R⁸)₂;

R² is selected from: H; unsubstituted or substituted C₁-8 alkyl,










unsubstituted or substituted aryl, ,  and -S(O)₂R⁶,

15 wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with
 one or two groups selected from:

- a) C₁-4 alkyl,
- b) (CH₂)_pOR⁶,
- 20 c) (CH₂)_pNR⁶R⁷,
- d) halogen,
- e) C₁-4 perfluoroalkyl,

- 2) C₃-6 cycloalkyl,
- 3) OR⁶,
- 25 4) SR⁶, S(O)R⁶, SO₂R⁶,



5

15) C₁₋₈ alkyl, or16) C₁₋₈ perfluoroalkyl;R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

5

R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

10

H; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:

- a) C₁₋₄ alkoxy,
- b) halogen, or
- c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

15

R⁸ is independently selected from hydrogen, C₁₋₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;




R⁹ is independently selected from C₁₋₆ alkyl and aryl;

20

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁₋₄ alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

25

- a) C₁₋₄ alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,



- h) $N(R^8)_2$, or
 i) C_{3-6} cycloalkyl;

5 R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

X is a bond, $-C(=O)NR^{10}$ -, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;


m is 0, 1 or 2;

p is 0, 1, 2, 3 or 4;

15 q is 0 or 1; and

or an optical isomer or pharmaceutically acceptable salt thereof.








In a preferred embodiment of this invention, the inhibitors
 20 of farnesyl-protein transferase are illustrated by the formula I:



I

wherein:

25 R^{1a} and R^{1c} are independently selected from: hydrogen, R^8O- , $-N(R^8)_2$, F, C_3-C_{10} cycloalkyl or C_1-C_6 alkyl;



15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

H; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:

- a) C₁₋₄ alkoxy,
- b) halogen, or
- c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

5

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;




R⁹ is independently selected from C₁-C₆ alkyl and aryl;

10

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁₋₄ alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

15

- a) C₁₋₄ alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,



20

- h) N(R⁸)₂, or
- i) C₃₋₆ cycloalkyl;

R¹¹ is selected from

25

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

A¹ is selected from: a bond, -C(O)-, O, -N(R⁸)-, or S(O)_m;

X is a bond, -C(=O)NR¹⁰-, -NR¹⁰C(=O)-, -S(O)_m- or -NR¹⁰-;

5

m is 0, 1 or 2;

n is 0 or 1;


p is 1, 2 or 3; and

q is 0 or 1;

10

or an optical isomer or pharmaceutically acceptable salt thereof.

Specific examples of the compounds of the invention are:



15

4-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5]pyridine-6(S)-carboxylic acid
(2-[3-(4-cyano-benzyl)-3H-imidazol-4-yl]-ethyl)-amide;

or an optical isomer or a pharmaceutically acceptable salt thereof.

20

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. When any
25 substituent, term, or variable (e.g. aryl, heterocycle, R^{1a}, R⁴ etc.) occurs more than one time in any formula or generic structure its definition on each occurrence is independent from the definition at every other occurrence. Also, combinations of substituents/or


variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge. "Halogen" or "halo" as used herein means fluoro, chloro, bromo and iodo.

As used herein, "aryl" is intended to mean any stable monocyclic, bicyclic or tricyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of monocyclic and bicyclic aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl. Examples of tricyclic aryl elements include 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl (which is also known as dibenzylsuberyl), 9-fluorenyl and 9,10-dihydroanthracen-9-yl. Preferably, "aryl" is a monocyclic or bicyclic carbon ring.

The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring or stable 13- to 15-membered tricyclic heterocyclic ring, which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of monocyclic and bicyclic heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl,

naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopyrrolidinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl. Examples of tricyclic heterocyclic elements include, but are not limited to, 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine, 9,10-dihydro-4H-3-thia-benzo[f]azulen-4-yl and 9-xanthenyl. The 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine moiety has the following structure:



Preferably, "heterocyclic" is a monocyclic or bicyclic moiety.

As used herein, "heteroaryl" is intended to mean any stable monocyclic, bicyclic or tricyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic and wherein from one to four carbon atoms are replaced by heteroatoms selected from the group consisting of N, O, and S. Examples of monocyclic and bicyclic heteroaryl elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiazolyl, thienofuryl, thienothienyl, and thienyl. Examples of tricyclic heteroaryl elements include, but are not limited to, 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine. Preferably, "heteroaryl" is a monocyclic or bicyclic moiety.

As used herein, "aralkyl" is intended to mean an aryl moiety, as defined above, attached through a C₁-C₆ alkyl linker, where alkyl is defined above. Examples of aralkyls include, but are not limited to, benzyl and naphthylmethyl.

5 As used herein, "heteroaralkyl" is intended to mean a heteroalkyl moiety, as defined above, attached through a C₁-C₆ alkyl linker, where alkyl is defined above. Examples of heteroaralkyls include, but are not limited to, 2-pyridylmethyl, 2-imidazolylethyl and 2-quinolinylmethyl.


10 As used herein, the term "substituted alkyl" is intended to include the branch or straight-chain alkyl group of 1 to 6 carbon atoms unless otherwise indicated, wherein the carbon atoms may be substituted with F, Cl, Br, CF₃, N₃, NO₂, NH₂, oxo, -OH, -O(C₁-C₆ alkyl), S(O)₀₋₂, (C₁-C₆ alkyl)S(O)₀₋₂, (C₁-C₆ alkyl)S(O)₀₋₂(C₁-C₆ alkyl)-, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, 15 -C(O)NH, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, -O(C₁-C₆ alkyl)CF₃, (C₁-C₆ alkyl)OC(O)-, (C₁-C₆ alkyl)O(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)C(O)2(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)OC(O)NH-, aryl, benzyl, heterocycle, aralkyl, heteroaralkyl, halo-aryl, halo-20 benzyl, halo-heterocycle, cyano-aryl, cyano-benzyl and cyano-heterocycle.

As used herein, the terms "substituted aryl", "substituted heterocycle", "substituted aralkyl", "substituted heteroaralkyl" and "substituted cycloalkyl" are intended to include 25 the cyclic group containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound. Such substituents are preferably selected from the group which includes but is not limited to F, Cl, Br, CF₃, NH₂, N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-30 C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)-, N₃, (C₁-C₆ alkyl)OC(O)NH- and C₁-C₂₀ alkyl.

When R⁶ and R⁷ or R⁷ and R^{7a} are combined to form a ring, cyclic amine moieties are formed. Examples of such cyclic moieties include, but are not limited to:



In addition, such cyclic moieties may optionally include another heteroatom(s). Examples of such heteroatom-containing
 5 cyclic amine moieties include, but are not limited to:



Lines drawn into the ring systems from substituents (such as from R^2 , R^3 , R^4 etc.) indicate that the indicated bond may be attached
 10 to any of the substitutable ring carbon or nitrogen atoms.

Preferably, R^{1a} and R^{1b} are independently selected from: hydrogen, $-N(R^8)_2$, $R^8C(O)NR^8-$ or C_1 - C_6 alkyl which is unsubstituted or substituted by $-N(R^8)_2$, R^8O- or $R^8C(O)NR^8-$.


15 Preferably, R^2 is selected from:

a) C_{1-8} alkyl, unsubstituted or substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with:


- 20 i) C_{1-4} alkyl,
 ii) $(CH_2)_pOR^6$,
 iii) $(CH_2)_pNR^6R^7$,

- iv) halogen,
- v) C₁₋₄ perfluoroalkyl,

- 2) OR⁶,
- 3) SR⁶, SO₂R⁶, or
- 4)  ;


5

b)



c) aryl, unsubstituted or substituted with one or more of:

10

- 1) C₁₋₈ alkyl,
- 2) C₁₋₈ perfluoroalkyl,
- 3) OR⁶,
- 4) SR⁶, SO₂R⁶, or
- 5)  ;

15

d) -SO₂R⁶.

Preferably, R² comprises at least one unsubstituted or substituted phenyl.

Preferably, R⁴ is selected from: hydrogen, perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, CN, NO₂, R⁸₂N-C(NR⁸)-, R⁸C(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₆ alkyl.

20

Preferably, R⁵ is hydrogen.

Preferably, R^{7b} is C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted aryl group.

Preferably, R⁸ is selected from H, C₁-C₆ alkyl and benzyl.

25

Preferably, A¹ and A² are independently selected from: a bond, -C(O)NR⁸-, -NR⁸C(O)-, O, -N(R⁸)-, -S(O)₂N(R⁸)- and -N(R⁸)S(O)₂-.

Preferably, V is selected from hydrogen, heterocycle and aryl.


Preferably, W is imidazolyl.

Preferably, X is a bond, $-C(=O)NR^{10}$ -, $-NR^{10}C(=O)-$ or $-NR^{10}$.


Preferably, n, p and r are independently 0, 1, or 2. More preferably, r is 1.

5 Preferably t is 1.

Preferably, the moiety



is selected from:



10

The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.

15

20

It is intended that the definition of any substituent or variable (e.g., R^{1a} , Z, n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus,

25

- N(R⁸)₂ represents -NH₂, -NHCH₃, -NHC₂H₅, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials.

The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.

Abbreviations used in the description of the chemistry and in the Examples that follow are:


| | |
|-------------------|---|
| Ac ₂ O | Acetic anhydride; |
| Boc | t-Butoxycarbonyl; |
| CBz | Carbobenzyloxy; |
| DBU | 1,8-diazabicyclo[5.4.0]undec-7-ene; |
| DMAP | 4-Dimethylaminopyridine; |
| DME | 1,2-Dimethoxyethane; |
| DMF | Dimethylformamide; |
| EDC | 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide- |
| hydrochloride; | |
| Et ₃ N | Triethylamine; |
| EtOAc | Ethyl acetate; |
| FAB | Fast atom bombardment; |
| HOBT | 1-Hydroxybenzotriazole hydrate; |
| HOBT | 3-Hydroxy-1,2,2-benzotriazin-4(3H)-one; |
| HPLC | High-performance liquid chromatography; |
| MCPBA | m-Chloroperoxybenzoic acid; |
| MsCl | Methanesulfonyl chloride; |
| NaHMDS | Sodium bis(trimethylsilyl)amide; |


Py Pyridine;
TFA Trifluoroacetic acid;
THF Tetrahydrofuran.

5 The compounds of this invention are prepared by employing
reactions as shown in Schemes 1-3, in addition to other standard
manipulations such as ester hydrolysis, cleavage of protecting groups,
etc., as may be known in the literature or exemplified in the
experimental procedures. While stereochemistry is shown in the
10 Schemes, a person of ordinary skill in the art would understand that the
illustrated compounds represent racemic mixtures which may be
separated at a subsequent purification step or may be utilized as the
racemic mixture.


15 These reactions may be employed in a linear sequence to
provide the compounds of the invention or they may be used to synthesize
fragments which are subsequently joined by the reductive alkylation or
acylation reactions described in the Schemes.


SCHEME 1





SCHEME 2

SCHEME 2A



SCHEME 2B

SCHEME 3

SCHEME 3 (CONT'D.)

In the above Schemes, it is understood that

R is R¹¹ or a protected precursor thereof; and

5 R' is R^{3a} or R^{3b} or protected precursor thereof.

The instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of
10 the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the *ras* genes themselves, mutations in the proteins that can regulate Ras activity (i.e.,
15 neurofibromin (NF-1), neu, scr, abl, lck, fyn) or by other mechanisms.

The compounds of the instant invention inhibit farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. The instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. *Cancer Research*, 55:4575-
20 4580 (1995)). Such anti-angiogenesis properties of the instant compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.

The compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant,
25 wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment. For example, the
30 compounds are useful in the treatment of neurofibromatosis, which is a benign proliferative disorder.

The instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. *Science*, 256:1331-1333 (1992)).

The compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. *Nature medicine*, 1:541-545(1995).

5 The instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffner et al. *American Journal of Pathology*, 142:1051-1060 (1993) and B. Cowley, Jr. et al. *FASEB Journal*, 2:A3160 (1988)).

10 The instant compounds may also be useful for the treatment of fungal infections.

 In a preferred embodiment of the instant invention the compounds of this instant invention are selective inhibitors of farnesyl-protein transferase. A compound is considered a selective inhibitor of farnesyl-protein transferase, for example, when its *in vitro* farnesyl-
15 protein transferase inhibitory activity, as assessed by the assay described in Example 2, is at least 100 times greater than the *in vitro* activity of the same compound against geranylgeranyl-protein transferase-type I in the assay described in Example 3. Preferably, a selective compound exhibits at least 1000 times greater activity against one of the enzymatic
20 activities when comparing geranylgeranyl-protein transferase-type I inhibition and farnesyl-protein transferase inhibition.

 In another preferred embodiment of the instant invention the compounds of this instant invention are dual inhibitors of farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such
25 a dual inhibitor will exhibit certain characteristics when assessed in *in vitro* assays, which are dependent on the type of assay employed.

 In a SEAP assay, such as described in Example 6, it is preferred that the dual inhibitor compound has an *in vitro* inhibitory activity (IC₅₀) that is less than about 12 μ M against K4B-Ras dependent
30 activation of MAP kinases in cells. More preferably, the dual inhibitor compound has an *in vitro* inhibitory activity (IC₅₀) against K4B-Ras dependent activation of MAP kinases in cells which is more than about 5 times lower than the inhibitory activity (IC₅₀) against Myr-Ras dependent activation of MAP kinases in cells. Also more preferably, in a

SEAP assay, the dual inhibitor compound has an inhibitory activity (IC₅₀) that is less than about 10 nM against H-Ras dependent activation of MAP kinases in cells.

In a GGTase plus anion assay, such as described in

- 5 Example 3, it is preferred that the dual inhibitor compound has an *in vitro* inhibitory activity (IC₅₀) that is less than about 5 μM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX^G motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion. More preferably, the dual
10 inhibitor compound has an *in vitro* inhibitory activity (IC₅₀) that is less than about 1 μM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX^G motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion. Preferably, the dual inhibitor compound has an *in vitro* inhibitory
15 activity (IC₅₀) in the *in vitro* assay as described in Example 2 that is less than about 1 μM against transfer of a farnesyl residue to a protein or peptide substrate, comprising a CAAX^F motif, by farnesyl-protein transferase. more preferably, the dual inhibitor compound has an *in vitro* inhibitory activity (IC₅₀) that is less than about 100nM against
20 transfer of a farnesyl residue to a protein or peptide substrate, comprising a CAAX^F motif, by farnesyl-protein transferase. Also preferably, the dual inhibitor compound has an *in vitro* inhibitory activity (IC₅₀) in the *in vitro* assay as described in Example 5, that is less than about 100 nM against the anchorage independent growth of H-ras-transformed mammalian fibroblasts.
25

- The protein or peptide substrate utilized in the instant assay may incorporate any CAAX motif that is geranylgeranylated by GGTase-I. The term "CAAX^G" will refer to such motifs that may be geranylgeranylated by GGTase-I. It is understood that some of the
30 "CAAX^G" containing protein or peptide substrates may also be farnesylated by farnesyl-protein transferase. In particular such "CAAX^G" motifs include (the corresponding human protein is in parentheses): CVIM (K4B-Ras) SEQ.ID.NO. 1, CVLL (mutated H-Ras) SEQ.ID.NO. 2, CVVM (N-Ras) SEQ.ID.NO. 3, CIIM (K4A-Ras)

SEQ.ID.NO 4, CLLL (Rap-IA) SEQ.ID.NO. 5, CQLL (Rap-IB)
SEQ.ID.NO. 6, CSIM SEQ.ID.NO. 7, CAIM SEQ.ID.NO. 8, CKVL
SEQ.ID.NO. 9 and CLIM SEQ.ID.NO. 10 (PFX). Preferably, the CAAX
motif is CVIM SEQ.ID.NO. 1.

5 As used herein, the term "CAAX^F" is used to designate a
protein or peptide substrate that incorporates four amino acid C-
terminus motif that is farnesylated by farnesyl-protein transferase. It is
understood that certain of the "CAAX^F" containing protein or peptide
substrates may also be geranylgeranylated by GGTase-I. In particular
10 such "CAAX^F" motifs include (the corresponding human protein is in
parentheses): CVLS (H-ras) SEQ.ID.NO. 11, CVIM (K4B-Ras)
SEQ.ID.NO. 1 and CVVM (N-Ras) SEQ.ID.NO.3.

 The compounds of this invention may be administered to
mammals, preferably humans, either alone or, preferably, in
15 combination with pharmaceutically acceptable carriers or diluents,
optionally with known adjuvants, such as alum, in a pharmaceutical
composition, according to standard pharmaceutical practice. The
compounds can be administered orally or parenterally, including the
intravenous, intramuscular, intraperitoneal, subcutaneous, rectal
20 and topical routes of administration.

 For oral use of a chemotherapeutic compound according
to this invention, the selected compound may be administered, for
example, in the form of tablets or capsules, or as an aqueous solution
or suspension. In the case of tablets for oral use, carriers which are
25 commonly used include lactose and corn starch, and lubricating
agents, such as magnesium stearate, are commonly added. For oral
administration in capsule form, useful diluents include lactose and
dried corn starch. When aqueous suspensions are required for oral
use, the active ingredient is combined with emulsifying and
30 suspending agents. If desired, certain sweetening and/or flavoring
agents may be added. For intramuscular, intraperitoneal,
subcutaneous and intravenous use, sterile solutions of the active
ingredient are usually prepared, and the pH of the solutions should
be suitably adjusted and buffered. For intravenous use, the total

concentration of solutes should be controlled in order to render the preparation isotonic.

The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.

When a compound according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.

The compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of farnesyl-protein transferase (FPTase) in a composition. Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate and, in one of the mixtures, a

compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to farnesylate the substrate, the chemical content of the assay mixtures may be determined by well known

5 immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the

10 assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.

It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain farnesyl-protein

15 transferase and quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of farnesyl-protein transferase, an excess

20 amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor (i.e., one that has a K_i

25 substantially smaller than the concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by 50% is approximately equal to half of the concentration of the enzyme in that particular sample.

30 EXAMPLES

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the

invention and not limitative of the reasonable scope thereof.
Purification by HPLC was utilized for Example 1 as set forth below.

EXAMPLE 1

5

Preparation of 4-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5] pyridine-6(S)-
carboxylic acid [2-[3-(4-cyano-benzyl)-3H -imidazol-4-yl]-ethyl]-amide

10 Step A: 4-phenyl-6,7-dihydro-4-H-imidazo[4,5]pyridine-1,5,6(S)-
tricarboxylic acid 1,5-di-tert-butyl ester

To a solution of L-histidine (3.1g, 0.02mol) and KOH (1.12g, 0.02mol) in water (50ml) and EtOH (50ml) was added benzaldehyde (3.06ml, 0.03mol). The resulting solution was heated at 70°C for 18h. The solvents were removed *in vacuo*. The residue was dissolved in THF (70ml) and water (30ml) and Boc anhydride (4.37g, 0.04mol) was added and the mixture was stirred for 18h at 25°C. The solvents were removed *in vacuo* and the residue was partitioned with EtOAc and water. The water layer was adjusted to pH=5 with 1M HCl and extracted twice with EtOAc. The EtOAc layers from the pH=5 extraction were combined and dried with brine and magnesium sulfate. The EtOAc was removed in *vacuo* to obtain the title compound as a solid which was used in the next step as is.

20 FAB mas spectrum m/e 444 (m+1).

25 Step B: 6(S)-{2-[3-(4-cyano-benzyl)-3H-imidazol-4yl]ethylcarbamoyl}-
4-phenyl-6,7-dihydro-4H-imidazo[4,5-] pyridine-1,5-
dicarboxylic acid di-tert-butyl ester

To a solution of the product as described in Step A above, [4-phenyl-6,7-dihydro-4-H-imidazo[4,5]pyridine-1,5,6(S)-tricarboxylic acid 1,5-di-tert-butyl ester] (0.34g, 0.826mm), cyanobenzyl histamine (5)(0.187g, 0.826mm), HOBt (0.126g, 0.826mm), EDC (0.158g, 0.826mm) in DMF (5ml) was added NMM (0.27ml, 2.48mm). The solvents were removed *in vacuo* and the residue was partitioned with EtOAc and saturated sodium bicarbonate. The EtOAc layer was dried with brine

Step C: 4-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5] pyridine-6(S)-
5 carboxylic acid {2-[3-(4-cyano-benzyl)-3H -imidazol-4-yl]-
ethyl}-amide

15 EXAMPLE 2

Assays of farnesyl-protein transferase. Partially purified bovine FPTase and Ras peptides (Ras-CVLS SEQ.ID.NO. 11, Ras-CVIM SEQ.ID.NO. 1 and Ras-CAIL SEQ.ID.NO. 12) were prepared as described by Schaber et al., J. Biol. Chem. 265:14701-14704 (1990), Pompliano, et al., Biochemistry 31:3800 (1992) and Gibbs et al., PNAS U.S.A. 86:6630-6634 (1989), respectively. Bovine FPTase was assayed in a volume of 100 μ l containing 100 mM *N*-(2-hydroxy ethyl) piperazine-*N*'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl₂, 5 mM dithiothreitol (DTT), 100 mM [³H]-farnesyl diphosphate ([³H]-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 mg/ml FPTase at 31°C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol. Precipitates were collected onto filter-mats using a TomTec Mach II cell harvester, washed with 100% ethanol, dried and counted in an LKB b-plate counter. The assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the [³H]-FPP was utilized during the reaction period. Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is

measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.

Human FPTase was prepared as described by Omer *et al.*,
5 Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed
as described above with the exception that 0.1% (w/v) polyethylene glycol
20,000, 10 mM ZnCl₂ and 100 nM Ras-CVIM were added to the reaction
mixture. Reactions were performed for 30 min., stopped with 100 ml of
10 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as
described above for the bovine enzyme.

The compounds of the instant invention described in the
above Examples were tested for inhibitory activity against human
FPTase by the assay described above and were found to have IC₅₀ of <50
15 μ M.

EXAMPLE 3

Modified *In vitro* GGTase inhibition assay

The modified geranylgeranyl-protein transferase inhibition
20 assay is carried out at room temperature. A typical reaction contains (in
a final volume of 50 mL): [³H]geranylgeranyl diphosphate, biotinylated
Ras peptide, 50 mM HEPES, pH 7.5, a modulating anion (for example 10
mM glycerophosphate or 5mM ATP), 5 mM MgCl₂, 10 mM ZnCl₂, 0.1%
PEG (15-20,000), 2 mM dithiothreitol, and geranylgeranyl-protein
25 transferase type I (GGTase). The GGTase-type I enzyme employed in the
assay is prepared as described in U.S. Pat. No. 5,470,832, incorporated by
reference. The Ras peptide is derived from the K4B-Ras protein and has
the following sequence: biotinyl-GKKKKKKSKTKCVIM (single amino
acid code) (SEQ.ID.NO.: 13). Reactions are initiated by the addition of
30 GGTase and stopped at timed intervals (typically 15 min) by the addition
of 200 μ L of a 3 mg/mL suspension of streptavidin SPA beads
(Scintillation Proximity Assay beads, Amersham) in 0.2 M sodium
phosphate, pH 4, containing 50 mM EDTA, and 0.5% BSA. The

quenched reactions are allowed to stand for 2 hours before analysis on a Packard TopCount scintillation counter.

For inhibition studies, assays are run as described above, except inhibitors are prepared as concentrated solutions in 100% dimethyl sulfoxide and then diluted 25-fold into the enzyme assay mixture. IC₅₀ values are determined with Ras peptide near K_M concentrations. Enzyme and nonsaturating substrate conditions for inhibitor IC₅₀ determinations are as follows: 75 pM GGTase-I, 1.6 mM Ras peptide, 100 nM geranylgeranyl diphosphate.

EXAMPLE 4

Cell-based *in vitro* ras prenylation assay

The cell lines used in this assay consist of either Rat1 or NIH3T3 cells transformed by either viral H-ras; an N-ras chimeric gene in which the C-terminal hypervariable region of viral-H-ras was substituted with the corresponding region from the N-ras gene; or ras-CVLL, a viral-H-ras mutant in which the C-terminal exon encodes leucine instead of serine, making the encoded protein a substrate for geranylgeranylation by GGTase-I. The assay can also be performed using cell lines transformed with human H-ras, N-ras or K4B-ras. The assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound(s) (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at 37°C, the cells are labelled in 3 ml methionine-free DMEM supplemented with 10% regular DMEM, 2% fetal bovine serum, 400 mCi[³⁵S]methionine (1000 Ci/mmol) and test compound(s). Cells treated with lovastatin, a compound that blocks Ras processing in cells by inhibiting the rate-limiting step in the isoprenoid biosynthetic pathway (Hancock, J.F. et al. *Cell*, 57:1167 (1989); DeClue, J.E. et al. *Cancer Res.*, 51:712 (1991); Sinensky, M. et al. *J. Biol. Chem.*, 265:19937 (1990)), serve as a positive control in this assay. After an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl₂/1mM DTT/10 mg/ml aprotinen/2

mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Alternatively, four hours after the addition of the labelling media, the media is removed, the cells washed, and 3 ml of media containing the same or a different test compound added. Following an additional 16 hour incubation, the lysis is carried out as above. Aliquots of lysates containing equal numbers of acid-precipitable counts are brought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. et al., J. Virol. 43:294-304, (1982)). Following a 2 hour antibody incubation at 4°C, 200 µl of a 25% suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 mM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100/0.5% deoxycholate/0.1%/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to prenylated and nonprenylated Ras proteins are compared to determine the percent inhibition of prenyl transfer to protein.

20

EXAMPLE 5

Cell-based *in vitro* anchorage independent growth assay (SALSA)

SALSA (Soft Agar-Like Surrogate Assay) measures the inhibition of anchorage-independent growth by prenyl-transferase inhibitors. Only transformed cells are able to grow anchorage-independently in the SALSA format. Additionally, cells growing in the SALSA format grow in clumps, resembling the colonies formed in soft agar. SALSA may be used to measure the growth inhibition by prenyl-transferase inhibitors in a variety of transformed cell lines, including Rat1 fibroblasts transformed with viral-H-ras (H-ras/rat1), as well as a panel of human tumor cell lines (HTL's).

SALSA is performed in 96-well plates that are coated with a thin film of the polymer, PolyHEMA (Poly(2-hydroxyethyl methacrylate)), which prevents cells from attaching to the plate.

35

Rat1 fibroblast cells transformed with v-Ha-ras (this cell line has been deposited in the ATCC on August 19, 1997 under the terms of the Budapest convention and has been given a designation of ATCC CRL 12387) are seeded at 5000 cells/well, grown for 4 hr, then vehicle or
5 half-log dilutions of test compound (in either an 8 or 12 point titration) are added. The cells are then grown for 6 days at 37 degrees, without changing the growth media or adding fresh compound. At day 6, cell growth is assessed via a colorimetric assay that measures the cleavage of the tetrazolium dye, MTT, to an insoluble purple
10 formazan, a reaction dependent upon mitochondrial dehydrogenases. At day 6, the cells are incubated for 4 hr with 0.5 mg/ml MTT, and then SDS is added to 9% w/v to lyse the cells and solubilize the insoluble MTT-formazan. The amount of MTT metabolism is quantitated via spectrophotometric detection at 570 nM.
15 Dose-inhibition curves and IC₅₀'s are determined.

EXAMPLE 6

Construction of SEAP reporter plasmid pDSE100

20 The SEAP reporter plasmid, pDSE100 was constructed by ligating a restriction fragment containing the SEAP coding sequence into the plasmid pCMV-RE-AKI. The SEAP gene is derived from the plasmid pSEAP2-Basic (Clontech, Palo Alto, CA). The plasmid pCMV-RE-AKI was constructed by Deborah Jones (Merck) and contains 5
25 sequential copies of the 'dyad symmetry response element' cloned upstream of a 'CAT-TATA' sequence derived from the cytomegalovirus immediate early promoter. The plasmid also contains a bovine growth hormone poly-A sequence.

The plasmid, pDSE100 was constructed as follows. A
30 restriction fragment encoding the SEAP coding sequence was cut out of the plasmid pSEAP2-Basic using the restriction enzymes EcoR1 and HpaI. The ends of the linear DNA fragments were filled in with the Klenow fragment of E. coli DNA Polymerase I. The 'blunt ended' DNA containing the SEAP gene was isolated by electrophoresing the digest in
35 an agarose gel and cutting out the 1694 base pair fragment. The vector

plasmid pCMV-RE-AKI was linearized with the restriction enzyme Bgl-II and the ends filled in with Klenow DNA Polymerase I. The SEAP DNA fragment was blunt end ligated into the pCMV-RE-AKI vector and the ligation products were transformed into DH5-alpha E. coli cells
5 (Gibco-BRL). Transformants were screened for the proper insert and then mapped for restriction fragment orientation. Properly oriented recombinant constructs were sequenced across the cloning junctions to verify the correct sequence. The resulting plasmid contains the SEAP coding sequence downstream of the DSE and CAT-TATA promoter
10 elements and upstream of the BGH poly-A sequence.

Cloning of a Myristylated viral-H-ras expression plasmid

A DNA fragment containing viral-H-ras can be PCR'd from plasmid "H-
15 1" (Ellis R. et al. J. Virol. 36, 408, 1980) using the following oligos.

Sense strand:

5'TCTCCTCGAGGCCACCATGGGGAGTAGCAAGAGCAAGCCTAA
GGACCCCAGCCAGCGCCGGATGACAGAATACAAGCTTGTGGTG
20 G 3'. (SEQ.ID.NO.: 14)

Antisense: 5'CACATCTAGATCAGGACAGCACAGACTTGCAGC 3'.
(SEQ.ID.NO.: 15)

25 A sequence encoding the first 15 aminoacids of the v-src gene, containing a myristylation site, is incorporated into the sense strand oligo. The sense strand oligo also optimizes the 'Kozak' translation initiation sequence immediately 5' to the ATG start site. To prevent prenylation at the viral-ras C-terminus, cysteine 186 would be mutated
30 to a serine by substituting a G residue for a C residue in the C-terminal antisense oligo. The PCR primer oligos introduce an XhoI site at the 5' end and a XbaI site at the 3' end. The XhoI-XbaI fragment can be ligated into the mammalian expression plasmid pCI (Promega) cut with XhoI and XbaI. This results in a plasmid in which the recombinant myr-

viral-H-ras gene is constitutively transcribed from the CMV promoter of the pCI vector.

5 Cloning of a viral-H-ras-CVLL expression plasmid

A viral-H-ras clone with a C-terminal sequence encoding the amino acids CVLL can be cloned from the plasmid "H-1" (Ellis R. et al. J. Virol. 36, 408, 1980) by PCR using the following oligos.

10

Sense strand:

5'TCTCCTCGAGGCCACCATGACAGAATACAAGCTTGTGGTGG-3'
(SEQ.ID.NO.: 16)

15 Antisense strand:

5'CACTCTAGACTGGTGTCTCAGAGCAGCACACACTTGCAGC-3'
(SEQ.ID.NO.: 17)

20 The sense strand oligo optimizes the 'Kozak' sequence and adds an XhoI site. The antisense strand mutates serine 189 to leucine and adds an XbaI site. The PCR fragment can be trimmed with XhoI and XbaI and ligated into the XhoI-XbaI cut vector pCI (Promega). This results in a plasmid in which the mutated viral-H-ras-CVLL gene is constitutively transcribed from the CMV promoter of the pCI vector.

25

Cloning of c-H-ras-Leu61 expression plasmid

The human c-H-ras gene can be PCR'd from a human cerebral cortex cDNA library (Clontech) using the following oligonucleotide primers.

30

Sense strand:

5'-GAGAGAATTTCGCCACCATGACGGAATATAAGCTGGTGG-3'
(SEQ.ID.NO.: 18)

Antisense strand:

5'-GAGAGTCGACGCGTCAGGAGAGCACACACTTGC-3'

(SEQ.ID.NO.: 19)

- 5 The primers will amplify a c-H-*ras* encoding DNA fragment with the primers contributing an optimized 'Kozak' translation start sequence, an EcoRI site at the N-terminus and a Sal I site at the C-terminal end. After trimming the ends of the PCR product with EcoRI and Sal I, the c-H-*ras* fragment can be ligated into an EcoRI -Sal I cut
- 10 mutagenesis vector pAlter-1 (Promega). Mutation of glutamine-61 to a leucine can be accomplished using the manufacturer's protocols and the following oligonucleotide:

5'-CCGCCGGCCTGGAGGAGTACAG-3' (SEQ.ID.NO.: 20)

15

- After selection and sequencing for the correct nucleotide substitution, the mutated c-H-*ras*-Leu61 can be excised from the pAlter-1 vector, using EcoRI and Sal I, and be directly ligated into the vector pCI (Promega) which has been digested with EcoRI and Sal I. The new
- 20 recombinant plasmid will constitutively transcribe c-H-*ras*-Leu61 from the CMV promoter of the pCI vector.

Cloning of a c-N-*ras*-Val-12 expression plasmid

- 25 The human c-N-*ras* gene can be PCR'd from a human cerebral cortex cDNA library (Clontech) using the following oligonucleotide primers.

Sense strand:

5'-GAGAGAATTTCGCCACCATGACTGAGTACAAACTGGTGG-3'

30 (SEQ.ID.NO.: 21)

Antisense strand:

5'-GAGAGTCGACTTGTTACATCACCACACATGGC-3' (SEQ.ID.NO.: 22)

The primers will amplify a *c-N-ras* encoding DNA fragment with the primers contributing an optimized 'Kozak' translation start sequence, an EcoRI site at the N-terminus and a Sal I site at the C-terminal end.

- 5 After trimming the ends of the PCR product with EcoRI and Sal I, the *c-N-ras* fragment can be ligated into an EcoRI -Sal I cut mutagenesis vector pAlter-1 (Promega). Mutation of glycine-12 to a valine can be accomplished using the manufacturer's protocols and the following oligonucleotide:

10

5'-GTTGGAGCAGTTGGTGGTGGG-3' (SEQ.ID.NO.: 23)

- After selection and sequencing for the correct nucleotide substitution, the mutated *c-N-ras-Val-12* can be excised from the pAlter-1 vector, using EcoRI and Sal I, and be directly ligated into the vector pCI (Promega) which has been digested with EcoRI and Sal I. The new recombinant plasmid will constitutively transcribe *c-N-ras-Val-12* from the CMV promoter of the pCI vector.

20 Cloning of a *c-K-ras-Val-12* expression plasmid

The human *c-K-ras* gene can be PCR'd from a human cerebral cortex cDNA library (Clontech) using the following oligonucleotide primers.

- 25 Sense strand:

5'-GAGAGGTACCGCCACCATGACTGAATATAAACTTGTGG-3'
(SEQ.ID.NO.: 24)

Antisense strand:

- 30 5'-CTCTGTCGACGTATTTACATAATTACACACTTTGTC-3'
(SEQ.ID.NO.: 25)

The primers will amplify a *c-K-ras* encoding DNA fragment with the primers contributing an optimized 'Kozak' translation start sequence, a

KpnI site at the N-terminus and a Sal I site at the C-terminal end. After trimming the ends of the PCR product with Kpn I and Sal I, the c-K-ras fragment can be ligated into a KpnI -Sal I cut mutagenesis vector pAlter-1 (Promega). Mutation of cysteine-12 to a valine can be
5 accomplished using the manufacturer's protocols and the following oligonucleotide:

5'-GTAGTTGGAGCTGTTGGCGTAGGC-3' (SEQ.ID.NO.: 26)

- 10 After selection and sequencing for the correct nucleotide substitution, the mutated c-K-ras-Val-12 can be excised from the pAlter-1 vector, using KpnI and Sal I, and be directly ligated into the vector pCI (Promega) which has been digested with KpnI and Sal I. The new recombinant plasmid will constitutively transcribe c-K-ras-Val-12 from
15 the CMV promoter of the pCI vector.

SEAP assay

- Human C33A cells (human epithelial carcinoma - ATTC collection) are seeded in 10cm tissue culture plates in DMEM + 10% fetal
20 calf serum + 1X Pen/Strep + 1X glutamine + 1X NEAA. Cells are grown at 37°C in a 5% CO₂ atmosphere until they reach 50 -80% of confluency.

- The transient transfection is performed by the CaPO₄ method (Sambrook et al., 1989). Thus, expression plasmids for H-ras, N-ras, K-ras, Myr-ras or H-ras-CVLL are co-precipitated with the DSE-
25 SEAP reporter construct. For 10cm plates 600ml of CaCl₂ -DNA solution is added dropwise while vortexing to 600ml of 2X HBS buffer to give 1.2ml of precipitate solution (see recipes below). This is allowed to sit at room temperature for 20 to 30 minutes. While the precipitate is forming, the media on the C33A cells is replaced with DMEM (minus phenol red;
30 Gibco cat. # 31053-028)+ 0.5% charcoal stripped calf serum + 1X (Pen/Strep, Glutamine and nonessential aminoacids). The CaPO₄-DNA precipitate is added dropwise to the cells and the plate rocked gently to distribute. DNA uptake is allowed to proceed for 5-6 hrs at 37°C under a 5% CO₂ atmosphere.

Following the DNA incubation period, the cells are washed with PBS and trypsinized with 1ml of 0.05% trypsin. The 1 ml of trypsinized cells is diluted into 10ml of phenol red free DMEM + 0.2% charcoal stripped calf serum + 1X (Pen/Strep, Glutamine and NEAA).

- 5 Transfected cells are plated in a 96 well microtiter plate (100ml/well) to which drug, diluted in media, has already been added in a volume of 100ml. The final volume per well is 200ml with each drug concentration repeated in triplicate over a range of half-log steps.

Incubation of cells and drugs is for 36 hrs at 37° under CO₂.

- 10 At the end of the incubation period, cells are examined microscopically for evidence of cell distress. Next, 100ml of media containing the secreted alkaline phosphatase is removed from each well and transferred to a microtube array for heat treatment at 65°C for 1 hr to inactivate endogenous alkaline phosphatases (but not the heat stable
15 secreted phosphatase).

The heat treated media is assayed for alkaline phosphatase by a luminescence assay using the luminescence reagent CSPD® (Tropix, Bedford, Mass.). A volume of 50 ml media is combined with 200 ml of CSPD cocktail and incubated for 60 minutes at room
20 temperature. Luminescence is monitored using an ML2200 microplate luminometer (Dynatech). Luminescence reflects the level of activation of the fos reporter construct stimulated by the transiently expressed protein.

25 DNA-CaPO₄ precipitate for 10cm. plate of cells

| | | |
|----|----------------------------------|-------|
| | Ras expression plasmid (1mg/ml) | 10ml |
| | DSE-SEAP Plasmid (1mg/ml) | 2ml |
| | Sheared Calf Thymus DNA (1mg/ml) | 8ml |
| 30 | 2M CaCl ₂ | 74ml |
| | dH ₂ O | 506ml |

2X HBS Buffer

- 280mM NaCl
10mM KCl
1.5mM Na₂HPO₄ 2H₂O
12mM dextrose
5 50mM HEPES
Final pH = 7.05

Luminescence Buffer (26ml)

- 10 Assay Buffer 20ml
Emerald Reagent™ (Tropix) 2.5ml
100mM homoarginine 2.5ml
CSPD Reagent® (Tropix) 1.0ml

15 Assay Buffer
Add 0.05M Na₂CO₃ to 0.05M NaHCO₃ to obtain pH 9.5. Make 1mM in
MgCl₂

EXAMPLE 7

- 20 *In vivo* tumor growth inhibition assay (nude mouse)

In vivo efficacy as an inhibitor of the growth of cancer cells may be confirmed by several protocols well known in the art. Examples of such *in vivo* efficacy studies are described by N. E. Kohl et al. (*Nature Medicine*, 1:792-797 (1995)) and N. E. Kohl et al. (*Proc. Nat. Acad. Sci.*


- 25 *U.S.A.*, 91:9141-9145 (1994)).

- Rodent fibroblasts transformed with oncogenically mutated human Ha-*ras* or Ki-*ras* (10⁶ cells/animal in 1 ml of DMEM salts) are injected subcutaneously into the left flank of 8-12 week old female nude mice (Harlan) on day 0. The mice in each oncogene group are randomly
30 assigned to a vehicle, compound or combination treatment group. Animals are dosed subcutaneously starting on day 1 and daily for the duration of the experiment. Alternatively, the farnesyl-protein transferase inhibitor may be administered by a continuous infusion

pump. Compound, compound combination or vehicle is delivered in a total volume of 0.1 ml. Tumors are excised and weighed when all of the vehicle-treated animals exhibited lesions of 0.5 - 1.0 cm in diameter, typically 11-15 days after the cells were injected. The average weight of
5 the tumors in each treatment group for each cell line is calculated.

WHAT IS CLAIMED IS:

1. A compound which inhibits farnesyl-protein transferase of the formula A:



5

A



wherein:

R^{1a}, R^{1b} and R^{1c} are independently selected from:

- a) hydrogen,
- 10 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-,
- 15 c) C₁-C₆ alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)-NR⁸-;

20

R² is selected from: H; unsubstituted or substituted C₁-8 alkyl, unsubstituted or substituted C₂-8 alkenyl, unsubstituted or substituted aryl,

unsubstituted or substituted heterocycle, ,  and -S(O)₂R⁶,

25 wherein the substituted group is substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:






- a) C₁₋₄ alkyl,
 b) (CH₂)_pOR⁶,
 c) (CH₂)_pNR⁶R⁷,
 d) halogen,
 e) C₁₋₄ perfluoroalkyl,

2) C₃₋₆ cycloalkyl,


3) OR⁶,

4) SR⁶, S(O)R⁶, SO₂R⁶,

5) —NR⁶R⁷,



11) —SO₂—NR⁶R⁷,





15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

5

R^{3a} and R^{3b} are independently absent or selected from: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

10

R⁴ is independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, R⁸₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NH-, CN, H₂N-C(NH)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁸OC(O)NH-;

15

20




R⁵ is independently selected from:

- a) hydrogen,
- b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C-(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and

25

- c) C₁-C₆ alkyl, unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-, C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

- 5 R⁶, R⁷ and R^{7a} are independently selected from: H; C₁-4 alkyl, C₃-6 cycloalkyl, heterocycle, aryl, C₁-4 perfluoroalkyl, unsubstituted or substituted with one or two substituents selected from:
- a) C₁-4 alkoxy,
- b) substituted or unsubstituted aryl or substituted or
- 10 c) halogen,
- d) HO,



- 15 h) N(R⁸)₂; or

R⁶ and R⁷ may be joined in a ring;

R⁷ and R^{7a} may be joined in a ring;




- 20 R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

- 25 R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, unsubstituted or substituted C₃-6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted

aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:

- 5 a) C₁₋₄ alkoxy,
 b) aryl or heterocycle,
 c) halogen,
 d) HO,



- 10 h) N(R⁸)₂, or
 i) C₃₋₆ cycloalkyl;

R¹¹ is selected from

- 15 H, unsubstituted or substituted alkyl, unsubstituted or
 substituted aryl, unsubstituted or substituted aralkyl,
 unsubstituted or substituted heteroaryl and unsubstituted or
 substituted heteroaralkyl;

- 20 A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-,
 -C(O)-, -C(O)NR⁸-, -NR⁸C(O)-, O, -N(R⁸)-, -S(O)₂N(R⁸)-, -
 N(R⁸)S(O)₂-, or S(O)_m;

J and K are independently selected from N, NH or CH_y;

- 25 V is selected from:

- a) hydrogen,
 b) heterocycle,

- c) aryl,
 - d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
 - e) C₂-C₂₀ alkenyl,
- 5 provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;


W is a heterocycle;

- 10 X is a bond, -C(=O)NR¹⁰-, -NR¹⁰C(=O)-, -S(O)_m-, -NR¹⁰-, O or -C(=O)-;

- m is 0, 1 or 2;
 - n is 0, 1, 2, 3 or 4;
 - p is 0, 1, 2, 3 or 4;
 - 15 q is 0, 1, 2, 3 or 4;
 - r is 0 to 5, provided that r is 0 when V is hydrogen;
 - s is 1 or 2;
 - t is 0 or 1; and
 - y is 1 or 2;
- 20 the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1, which inhibits
- 25 farnesyl-protein transferase, of the formula B:



B

wherein:


R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₁-C₆ alkyl;

5


R^{1b} is independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₆ cycloalkyl, R⁸O-, -N(R⁸)₂ or C₂-C₆ alkenyl,
- 10 c) C₁-C₆ alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;

15 R² is selected from:


- a) C₁-8 alkyl, unsubstituted or substituted with one or more of:
 - 1) aryl or heterocycle, unsubstituted or substituted with:
 - 20 i) C₁-4 alkyl,
 - ii) (CH₂)_pOR⁶,
 - iii) (CH₂)_pNR⁶R⁷,
 - iv) halogen,
 - v) C₁-4 perfluoroalkyl,
 - 25 2) OR⁶,
 - 3) SR⁶, SO₂R⁶, or
 - 4)  ;

b)



30

c) aryl, unsubstituted or substituted with one or more of:

- 1) C₁₋₈ alkyl,
- 2) C₁₋₈ perfluoroalkyl,
- 3) OR⁶,
- 4) SR⁶, SO₂R⁶, or
- 5)  ;

d) -SO₂R⁶;

10 R^{3a} and R^{3b} are independently absent or selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

15

R⁴ is independently selected from:

- a) hydrogen,
- b) C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- 20 c) C₁₋₆ alkyl substituted by C₁₋₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

25 R⁵ is selected from:

- a) hydrogen,
- b) C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₆ perfluoroalkyl, F, Cl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or
- 30 R⁹OC(O)NR⁸-, and
- c) C₁₋₆ alkyl unsubstituted or substituted by C₁₋₆ perfluoroalkyl, F, Cl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN,




$(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $R^8OC(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$;

- 5 R^6 , R^7 and R^{7a} are independently selected from:
 H; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, aryl, heterocycle,
 unsubstituted or substituted with:
 a) C₁₋₄ alkoxy,
 b) halogen, or
 c) substituted or unsubstituted aryl or substituted or
 10 unsubstituted heterocycle;

R^8 is independently selected from hydrogen, C_{1-C6} alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

- 15 R^9 is independently selected from C_{1-C6} alkyl and aryl;

- R^{10} is selected from: H; $R^8C(O)-$; $R^9S(O)_m-$; unsubstituted or substituted C₁₋₄ alkyl, unsubstituted or substituted C₃₋₆ cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted
 20 aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:
 a) C₁₋₄ alkoxy,
 b) aryl or heterocycle,
 c) halogen,
 25 d) HO,



- h) $N(R^8)_2$, or
- i) C₃₋₆ cycloalkyl;

5 R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A^1 and A^2 are independently selected from: a bond, $-CH=CH-$, $-C\equiv C-$, $-C(O)-$, $-C(O)NR^8-$, O, $-N(R^8)-$, or $S(O)_m$;

J and K are independently selected from N or CH_y ;

15

V is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl, and

20

- b) aryl;

W is a heterocycle selected from pyrrolidinyl, triazolyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, or isoquinolinyl;

25 X is a bond, $-C(=O)NR^{10}-$, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;

m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 1, 2 or 3;

30 q is 0 or 1;

r is 0 to 5, provided that r is 0 when V is hydrogen;

s is 1 or 2;

t is 1; and


y is 1 or 2;

the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

5

3. The compound according to Claim 1, which inhibits farnesyl-protein transferase, of the formula C:



10 wherein:

R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₁-C₆ alkyl;

15 R^{1b} is independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₆ cycloalkyl, R⁸O-, -N(R⁸)₂ or C₂-C₆ alkenyl,
- 20 c) C₁-C₆ alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;


R² is selected from:

- 25 a) C₁-8 alkyl, unsubstituted or substituted with one or more of:


1) aryl or heterocycle, unsubstituted or substituted with:

- i) C₁₋₄ alkyl,
- ii) (CH₂)_pOR⁶,
- iii) (CH₂)_pNR⁶R⁷,
- iv) halogen,
- v) C₁₋₄ perfluoroalkyl,

- 2) OR⁶,
- 3) SR⁶, SO₂R⁶, or
- 4)




b)



c) aryl, unsubstituted or substituted with one or more of:

- 1) C₁₋₈ alkyl,
- 2) C₁₋₈ perfluoroalkyl,
- 3) OR⁶,
- 4) SR⁶, SO₂R⁶, or
- 5)



d) -SO₂R⁶;

R^{3a} and R^{3b} are independently absent or selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

- a) hydrogen,

- b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- 5 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

R⁵ is selected from:

- a) hydrogen,
- 10 b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- 15 c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

R⁶, R⁷ and R^{7a} are independently selected from:

- 20 H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:
- a) C₁-4 alkoxy,
- b) halogen, or
- 25 c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;




R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

30 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, unsubstituted or substituted C₃-6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted

aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:

- 5 a) C₁₋₄ alkoxy,
b) aryl or heterocycle,
c) halogen,
d) HO,



- 10 h) N(R⁸)₂, or
i) C₃₋₆ cycloalkyl;

R¹¹ is selected from

- 15 H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaroyl and unsubstituted or substituted heteroaralkyl;

- 20 A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR⁸-, O, -N(R⁸)-, or S(O)_m;

V is selected from:

- 25 a) heterocycle selected from pyrrolidinyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl; and
b) aryl;

W is a heterocycle selected from pyrrolidinyl, triazolyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, or isoquinolinyl;

X is a bond, $-C(=O)NR^{10}$ -, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}$;

5

m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 1, 2 or 3;

q is 0 or 1;

10

r is 0 to 5, provided that r is 0 when V is hydrogen;

s is 1 or 2; and


t is 1;

the dashed lines represent optional double bonds;

15

or an optical isomer or pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1, which inhibits farnesyl-protein transferase, of the formula D:



20

D

wherein:

R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₁-C₆ alkyl;



25

R^{1b} is independently selected from:

a) hydrogen,




- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₂-C₆ alkenyl,
- c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R⁸O- and -N(R⁸)₂;






R² is selected from: H; unsubstituted or substituted C₁-8 alkyl, unsubstituted or substituted C₂-8 alkenyl, unsubstituted or substituted aryl,

- 10 unsubstituted or substituted heterocycle, ,  and -S(O)₂R⁶,

wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:
- 15 a) C₁-4 alkyl,
 b) (CH₂)_pOR⁶,
 c) (CH₂)_pNR⁶R⁷,
 d) halogen,
 e) C₁-4 perfluoroalkyl,
- 20 2) C₃-6 cycloalkyl,
 3) OR⁶,
 4) SR⁶, S(O)R⁶, SO₂R⁶,





15) C₁-8 alkyl, or

16) C₁-8 perfluoroalkyl;

R^{3a} and R^{3b} are independently absent or selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

a) hydrogen,

b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

- perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;




R^{5a} and R^{5b} are independently hydrogen, C₁-C₆ alkyl, cyclopropyl, trifluoromethyl and halogen;

- 10 R⁶, R⁷ and R^{7a} are independently selected from:
H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle,
unsubstituted or substituted with:
a) C₁-4 alkoxy,
b) halogen, or
15 c) substituted or unsubstituted aryl or substituted or
unsubstituted heterocycle;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;

- 20 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

- R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, unsubstituted or substituted C₃-6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:
- 25 a) C₁-4 alkoxy,
30 b) aryl or heterocycle,
c) halogen,
d) HO,



h) $\text{N}(\text{R}^8)_2$, or

i) C₃₋₆ cycloalkyl;

5

R¹¹ is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A¹ and A² are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^8-$, O, $-\text{N}(\text{R}^8)-$, or $\text{S}(\text{O})_m$;

15 J and K are independently selected from N or CH_y;

V is selected from:

- a) hydrogen,
- b) heterocycle selected from pyrrolidinyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
- c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl, and

25

provided that V is not hydrogen if A¹ is $\text{S}(\text{O})_m$ and V is not hydrogen if A¹ is a bond, n is 0 and A² is $\text{S}(\text{O})_m$;

X is a bond, $-C(=O)NR^{10}-$, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;

m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

5 p is 0, 1, 2, 3 or 4;

q is 0 or 1;


r is 0 to 5, provided that r is 0 when V is hydrogen; and

y is 1 or 2;

10 the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1, which inhibits
15 farnesyl-protein transferase, of the formula E:



wherein:

20 R¹ᵃ and R¹ᶜ are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₁-C₆ alkyl;

R¹ᵇ is independently selected from:

- 25 a) hydrogen,
b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₂-C₆ alkenyl,
c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from




unsubstituted or substituted aryl, heterocycle, C₃-C₁₀
cycloalkyl, C₂-C₆ alkenyl, R⁸O- and -N(R⁸)₂;

- R² is selected from: H; unsubstituted or substituted C₁-8 alkyl,
5 unsubstituted or substituted C₂-8 alkenyl, unsubstituted or substituted aryl,






unsubstituted or substituted heterocycle, $\text{C}(=\text{O})\text{R}^6$, $\text{C}(=\text{O})\text{NR}^6\text{R}^7$ and -
S(O)₂R⁶,

wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with
10 one or two groups selected from:
a) C₁-4 alkyl,
b) (CH₂)_pOR⁶,
c) (CH₂)_pNR⁶R⁷,
d) halogen,
15 e) C₁-4 perfluoroalkyl,
2) C₃-6 cycloalkyl,
3) OR⁶,
4) SR⁶, S(O)R⁶, SO₂R⁶,



20



15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} and R^{3b} are independently absent or selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

a) hydrogen,

b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

- perfluoroalkyl, F, Cl, R^8O- , $R^8C(O)NR^8-$, CN, NO_2 , $(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$, and
- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R^8O- , $R^8C(O)NR^8-$, $(R^8)_2N-C(NR^8)-$, $R^8C(O)-$, $-N(R^8)_2$, or $R^9OC(O)NR^8-$;




R^{5a} and R^{5b} are independently hydrogen, C₁-C₆ alkyl, cyclopropyl, trifluoromethyl and halogen;

- 10 R^6 , R^7 and R^{7a} are independently selected from:
H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle,
unsubstituted or substituted with:
a) C₁-4 alkoxy,
b) halogen, or
15 c) substituted or unsubstituted aryl or substituted or
unsubstituted heterocycle;

R^8 is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;

- 20 R^9 is independently selected from C₁-C₆ alkyl and aryl;

- R^{10} is selected from: H; $R^8C(O)-$; $R^9S(O)_m-$; unsubstituted or substituted C₁-4 alkyl, unsubstituted or substituted C₃-6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from:
- 25 a) C₁-4 alkoxy,
30 b) aryl or heterocycle,
c) halogen,
d) HO,



h) $\text{N(R}^8)_2$, or

i) C₃₋₆ cycloalkyl;

5

R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

A^1 and A^2 are independently selected from: a bond, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{C(O)}-$, $-\text{C(O)NR}^8-$, O, $-\text{N(R}^8)-$, or S(O)_m ;

15 V is selected from:

a) hydrogen,

b) heterocycle selected from pyrrolidinyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,

20

c) aryl,

d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and

e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A^1 is S(O)_m and V is not hydrogen if

25 A^1 is a bond, n is 0 and A^2 is S(O)_m ;

X is a bond, $-\text{C(=O)NR}^{10}-$, $-\text{NR}^{10}\text{C(=O)}-$, $-\text{S(O)}_m-$ or $-\text{NR}^{10}-$;


- m is 0, 1 or 2;
 n is 0, 1, 2, 3 or 4;
 p is 0, 1, 2, 3 or 4;
 q is 0 or 1; and
 5 r is 0 to 5, provided that r is 0 when V is hydrogen;

the dashed lines represent optional double bonds;

or an optical isomer or pharmaceutically acceptable salt thereof.

10

6. The compound according to Claim 5, which inhibits farnesyl-protein transferase, of the formula F:



15 wherein:

R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

20 R^{1b} is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₂-C₆ alkenyl,
- c) C₁-C₆ alkyl unsubstituted or substituted by aryl,
- 25 heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;

R^2 is selected from: H; unsubstituted or substituted C_{1-8} alkyl,

unsubstituted or substituted aryl, $\begin{array}{c} R^6 \\ \diagup \\ C=O \end{array}$, $\begin{array}{c} NR^6R^7 \\ \diagup \\ C=O \end{array}$ and $-S(O)_2R^6$,

wherein the substituted group is substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:






- a) C_{1-4} alkyl,
- b) $(CH_2)_pOR^6$,
- c) $(CH_2)_pNR^6R^7$,
- d) halogen,
- e) C_{1-4} perfluoroalkyl,

- 2) C_{3-6} cycloalkyl,
- 3) OR^6 ,
- 4) SR^6 , $S(O)R^6$, SO_2R^6 ,

5) $-NR^6R^7$,

6) $\begin{array}{c} R^6 \\ | \\ -N-C(=O)-R^7 \end{array}$,

7) $\begin{array}{c} R^6 \\ | \\ -N-C(=O)-NR^7R^{7a} \end{array}$,



15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R⁴ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and

- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

5 R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:




- 10 a) C₁-4 alkoxy,
b) halogen, or
c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

15 R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

20 R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

- a) C₁-4 alkoxy,
b) aryl or heterocycle,
25 c) halogen,
d) HO,



- h) $N(R^8)_2$, or
 i) C_{3-6} cycloalkyl;

5 R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10


A^1 is selected from: a bond, $-C(O)-$, O, $-N(R^8)-$, or $S(O)_m$;

X is a bond, $-C(=O)NR^{10}-$, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;

- 15 n is 0 or 1; provided that n is not 0 if A^1 is a bond, O, $-N(R^8)-$, or $S(O)_m$;
 m is 0, 1 or 2;
 p is 0, 1, 2, 3 or 4;
 r is 1 or 2; and
 20 q is 0 or 1;

or an optical isomer or pharmaceutically acceptable salt thereof.

7. The compound according to Claim 1, which inhibits
 25 farnesyl-protein transferase, of the formula G:



wherein:



R^{1a} and R^{1c} are independently selected from: hydrogen, R⁸O-, -N(R⁸)₂, F, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

5

R^{1b} is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R⁸O-, -N(R⁸)₂, F or C₂-C₆ alkenyl,
- 10 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -N(R⁸)₂;

R² is selected from: H; unsubstituted or substituted C₁-8 alkyl,

- 15 unsubstituted or substituted aryl, ,  and -S(O)₂R⁶,

wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:
 - a) C₁-4 alkyl,
 - 20 b) (CH₂)_pOR⁶,
 - c) (CH₂)_pNR⁶R⁷,
 - d) halogen,
 - e) C₁-4 perfluoroalkyl,
- 2) C₃-6 cycloalkyl,
- 25 3) OR⁶,
- 4) SR⁶, S(O)R⁶, SO₂R⁶,

- 5) $-\text{NR}^6\text{R}^7$,
- 6) $-\text{N}(\text{R}^6)\text{C}(=\text{O})\text{R}^7$,
- 7) $-\text{N}(\text{R}^6)\text{C}(=\text{O})\text{NR}^7\text{R}^{7a}$,
- 8) $-\text{O}\text{C}(=\text{O})\text{NR}^6\text{R}^7$,
- 9) $-\text{O}\text{C}(=\text{O})\text{OR}^6$,
- 10) $\text{CH}_3\text{C}(=\text{O})\text{NR}^6\text{R}^7$,
- 11) $-\text{SO}_2-\text{NR}^6\text{R}^7$,
- 12) $-\text{N}(\text{R}^6)\text{SO}_2-\text{R}^7$,
- 13) $\text{CH}_3\text{C}(=\text{O})\text{R}^6$,
- 14) $\text{CH}_3\text{C}(=\text{O})\text{OR}^6$,
- 15) C₁₋₈ alkyl, or
- 16) C₁₋₈ perfluoroalkyl;

5

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

5

R⁴ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, substituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R⁸O-, R⁸C(O)NR⁸-, CN, NO₂, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-, and
- c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R⁸O-, R⁸C(O)NR⁸-, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, -N(R⁸)₂, or R⁹OC(O)NR⁸-;

15

R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

- H; C₁-4 alkyl, C₃-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:
- a) C₁-4 alkoxy,
 - b) halogen, or
 - c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

25

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;




R⁹ is independently selected from C₁-C₆ alkyl and aryl;

30

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁-4 alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

- a) C₁-4 alkoxy,

- b) aryl or heterocycle,
- c) halogen,
- d) HO,



5

- h) $\text{N}(\text{R}^8)_2$, or
- i) C_{3-6} cycloalkyl;

R^{11} is selected from

- 10 H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

- 15 X is a bond, $-\text{C}(=\text{O})\text{NR}^{10}-$, $-\text{NR}^{10}\text{C}(=\text{O})-$, $-\text{S}(\text{O})_m-$ or $-\text{NR}^{10}-$;

n is 0 or 1;

m is 0, 1 or 2;

p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond, $-\text{NR}^8-$ or


20 O;

q is 0 or 1; and

r is 1 or 2;

or an optical isomer or pharmaceutically acceptable salt thereof.

- 25 8. The compound according to Claim 6, which inhibits farnesyl-protein transferase, of the formula H:





wherein:

5 R^{1a} and R^{1c} are independently selected from: hydrogen, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

R^{1b} is independently selected from:










- 10 a) hydrogen,
 b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R^8O- , $-N(R^8)_2$ or F,
 c) C₁-C₆ alkyl unsubstituted or substituted by aryl,
 heterocycle, C₃-C₁₀ cycloalkyl, R^8O- , or $-N(R^8)_2$;

R^2 is selected from: H; unsubstituted or substituted C₁-8 alkyl,

unsubstituted or substituted aryl, ,  and $-S(O)_2R^6$,

15 wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with one or two groups selected from:
 a) C₁-4 alkyl,
 b) $(CH_2)_pOR^6$,
 20 c) $(CH_2)_pNR^6R^7$,
 d) halogen,
 e) C₁-4 perfluoroalkyl,
 2) C₃-6 cycloalkyl,
 3) OR^6 ,
 25 4) SR^6 , $S(O)R^6$, SO_2R^6 ,



5

15) C₁₋₈ alkyl, or16) C₁₋₈ perfluoroalkyl;

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

5

R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R⁶, R⁷ and R^{7a} are independently selected from:

10

H; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:

- a) C₁₋₄ alkoxy,
- b) halogen, or
- c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

15

R⁸ is independently selected from hydrogen, C₁₋₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;




R⁹ is independently selected from C₁₋₆ alkyl and aryl;

20

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁₋₄ alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

25

- a) C₁₋₄ alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,



- h) $N(R^8)_2$, or
 i) C3-6 cycloalkyl;

5 R^{11} is selected from

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

10

X is a bond, $-C(=O)NR^{10}-$, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;


m is 0, 1 or 2;

p is 0, 1, 2, 3 or 4;

15 q is 0 or 1; and

or an optical isomer or pharmaceutically acceptable salt thereof.

9. The compound according to Claim 7, which inhibits
 20 farnesyl-protein transferase, of the formula I:



wherein:

25 R^{1a} and R^{1c} are independently selected from: hydrogen, R^8O- , $-N(R^8)_2$,
 F, C3-C10 cycloalkyl or C1-C6 alkyl;

R^{1b} is independently selected from:



- a) hydrogen,
- b) aryl, heterocycle or C₃-C₁₀ cycloalkyl,
- c) C₁-C₆ alkyl unsubstituted or substituted by aryl,
 5 heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R⁸O-, or -
 N(R⁸)₂;








R² is selected from: H; unsubstituted or substituted C₁-8 alkyl,

unsubstituted or substituted aryl, $\text{C}(=\text{O})\text{R}^6$, $\text{C}(=\text{O})\text{NR}^6\text{R}^7$ and -S(O)₂R⁶,

10 wherein the substituted group is substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with
 one or two groups selected from:
 - a) C₁-4 alkyl,
 - b) (CH₂)_pOR⁶,
 - 15 c) (CH₂)_pNR⁶R⁷,
 - d) halogen,
 - e) C₁-4 perfluoroalkyl,
- 2) C₃-6 cycloalkyl,
- 3) OR⁶,
- 20 4) SR⁶, S(O)R⁶, SO₂R⁶,





15) C₁₋₈ alkyl, or

16) C₁₋₈ perfluoroalkyl;

R^{3a} is selected from:

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aralkyl and unsubstituted or substituted heteroaralkyl;

R^{5a} and R^{5b} are independently hydrogen, ethyl, cyclopropyl or methyl;

15 R⁶, R⁷ and R^{7a} are independently selected from:

H; C₁₋₄ alkyl, C₃₋₆ cycloalkyl, aryl, heterocycle, unsubstituted or substituted with:

- a) C₁₋₄ alkoxy,
- b) halogen, or
- c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;

5

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl, 2,2,2-trifluoroethyl, benzyl and aryl;




R⁹ is independently selected from C₁-C₆ alkyl and aryl;

10

R¹⁰ is selected from: H; R⁸C(O)-; R⁹S(O)_m-; unsubstituted or substituted C₁₋₄ alkyl, wherein the substituted alkyl group is substituted with one or two substituents selected from:

15

- a) C₁₋₄ alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,



20

- h) N(R⁸)₂, or
- i) C₃₋₆ cycloalkyl;

R¹¹ is selected from

25

H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heteroaralkyl;

A^1 is selected from: a bond, $-C(O)-$, O , $-N(R^8)-$, or $S(O)_m$;

X is a bond, $-C(=O)NR^{10}-$, $-NR^{10}C(=O)-$, $-S(O)_m-$ or $-NR^{10}-$;

5

m is 0, 1 or 2;

n is 0 or 1;


p is 1, 2 or 3; and

q is 0 or 1;

10

or an optical isomer or pharmaceutically acceptable salt thereof.

10. A compound which inhibits farnesyl-protein transferase which is:



15

4-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5]pyridine-6(S)-carboxylic acid {2-[3-(4-cyano-benzyl)-3H-imidazol-4-yl]-ethyl}-amide;

or an optical isomer or pharmaceutically acceptable salt thereof.

20

11. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

25

12. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 3.

13. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

5 14. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 5.

10 15. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 10.

15 16. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 11.

20 17. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 12.

25 18. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 13.

30 19. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 14.

20. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need

thereof a therapeutically effective amount of a composition of Claim 15.

21. A method for treating cancer which comprises
5 administering to a mammal in need thereof a therapeutically
effective amount of a composition of Claim 11.

22. A method for treating cancer which comprises
administering to a mammal in need thereof a therapeutically
10 effective amount of a composition of Claim 12.

23. A method for treating cancer which comprises
administering to a mammal in need thereof a therapeutically
effective amount of a composition of Claim 13.

15 24. A method for treating cancer which comprises
administering to a mammal in need thereof a therapeutically
effective amount of a composition of Claim 14.

20 25. A method for treating cancer which comprises
administering to a mammal in need thereof a therapeutically
effective amount of a composition of Claim 15.

25 26. A method for treating neurofibromin benign
proliferative disorder which comprises administering to a mammal in
need thereof a therapeutically effective amount of a composition of Claim
11.

27. A method for treating blindness related to retinal
30 vascularization which comprises administering to a mammal in need
thereof a therapeutically effective amount of a composition of Claim 11.

28. A method for treating infections from hepatitis delta
and related viruses which comprises administering to a mammal in

need thereof a therapeutically effective amount of a composition of Claim 11.

29. A method for preventing restenosis which comprises
5 administering to a mammal in need thereof a therapeutically effective
amount of a composition of Claim 11.

30. A method for treating polycystic kidney disease which
comprises administering to a mammal in need thereof a therapeutically
10 effective amount of a composition of Claim 11.

31. A pharmaceutical composition made by combining
the compound of Claim 1 and a pharmaceutically acceptable carrier.

32. A process for making a pharmaceutical composition
15 comprising combining a compound of Claim 1 and a pharmaceutically
acceptable carrier.

20

SEQUENCE LISTING

<110> Ciccarone, Terrence M.
deSolms, Jane S. J.
Merck & Co., Inc.

<120> INHIBITORS OF FARNESYL-PROTEIN
TRANSFERASE

<130> 20121Y

<150> 60/067,552

<151> 1997-12-04

<160> 26

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 4

<212> PRT

<213> Homosapien

<400> 1

Cys Val Ile Met

1

<210> 2

<211> 4

<212> PRT

<213> Homosapien

<400> 2

Cys Val Leu Leu

1

<210> 3

<211> 4

<212> PRT

<213> Homosapien

<400> 3

Cys Val Val Met

1

<210> 4

<211> 4

<212> PRT

<213> Homosapien

<400> 4

Cys Ile Ile Met

1

<210> 5
<211> 4
<212> PRT
<213> Homosapien

<400> 5
Cys Leu Leu Leu
1

<210> 6
<211> 4
<212> PRT
<213> Homosapien

<400> 6
Cys Gln Leu Leu
1

<210> 7
<211> 4
<212> PRT
<213> Homosapien

<400> 7
Cys Ser Ile Met
1

<210> 8
<211> 4
<212> PRT
<213> Homosapien

<400> 8
Cys Ala Ile Met
1

<210> 9
<211> 4
<212> PRT
<213> Homosapien

<400> 9
Cys Lys Val Leu
1

<210> 10
<211> 4
<212> PRT
<213> Homosapien

<400> 10
Cys Leu Ile Met
1

<210> 11
<211> 4

<212> PRT
 <213> Homosapien

<400> 11
 Cys Val Leu Ser
 1

<210> 12
 <211> 4
 <212> PRT
 <213> Homosapien

<400> 12
 Cys Ala Ile Leu
 1

<210> 13
 <211> 15
 <212> PRT
 <213> Homosapien

<400> 13
 Gly Lys Lys Lys Lys Lys Lys Ser Lys Thr Lys Cys Val Ile Met
 1 5 10 15

<210> 14
 <211> 86
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> completely synthesized

<400> 14
 tctcctcgag gccaccatgg ggagtagcaa gagcaagcct aaggacccca gccagcgccg 60
 gatgacagaa tacaagcttg tgggtgg 86

<210> 15
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> completely synthesized

<400> 15
 cacatctaga tcaggacagc acagacttgc agc 33

<210> 16
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> completely synthesized

<400> 16
tctcctcgag gccaccatga cagaatacaa gcttggtg g 41

<210> 17
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 17
cactctagac tgggtgcaga gcagcacaca cttgcagc 38

<210> 18
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 18
gagagaattc gccaccatga cggaatataa gctggtgg 38

<210> 19
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 19
gagagtcgac gcgtcaggag agcacacact tgc 33

<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 20
ccgccggcct ggaggagtac ag 22

<210> 21
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 21

gagagaattc gccaccatga ctgagtacaa actgggtgg 38

<210> 22
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 22
gagagtcgac ttgttacatc accacacatg gc 32

<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 23
gttgagcag ttggtgttg g 21

<210> 24
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 24
gagaggtacc gccaccatga ctgaatataa acttgtgg 38

<210> 25
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 25
ctctgtcgac gtatttacat aattacacac ttgtgc 36

<210> 26
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> completely synthesized

<400> 26
gtagttggag ctggtggcgt aggc 24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/25325

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/435; C07D 471/04

US CL : 514/303; 546/118

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/303; 546/118

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN-REGISTRY FILE - STRUCTURE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | US 5,262,537 A (HUANG et al.) 16 November 1993, see entire document. | 1-5 and 11-15 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *B* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

21 JANUARY 1999

Date of mailing of the international search report

05 FEB 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

B. DENTZ aco

Telephone No. (703) 308-1235